2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDB
2012
Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?
Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.Peer-Reviewed Original ResearchBreast cancer patientsLN statusCancer patientsLymphovascular invasionTumor sizeTumor markersPositive LNsPoor prognosisMedian numberPrimary tumor markersMedian patient ageMedian tumor sizeLymph node positivityLN-positive patientsLymph node statusOnly factorCancer initiating cellsCancer-initiating cellsLevels of CD44Axillary surgeryLN positivityNode positivityPatient agePositive patientsClinicopathologic dataAccuracy of breast MRI in predicting pathologic tumor size.
Caprio K, Chagpar A, Hooley R, Tavassoli F, Honarpishe H, Lannin D, Killelea B, Horowitz N. Accuracy of breast MRI in predicting pathologic tumor size. Journal Of Clinical Oncology 2012, 30: 1109-1109. DOI: 10.1200/jco.2012.30.15_suppl.1109.Peer-Reviewed Original ResearchPathologic tumor sizeTumor sizeAccuracy of MRIMRI sizePathologic sizePathology sizeBreast cancerMRI lesion sizeSitu breast cancerPreoperative planning toolFinal pathologyNeoadjuvant chemotherapyPatient agePathologic findingsTumor histologyPreoperative MRILesion sizeLesionsBreast MRISpearman's rho coefficientPatientsMRICancerModest correlationSpearman coefficient
2011
P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.Peer-Reviewed Original ResearchDuctal intraepithelial neoplasiaHormone receptor statusReceptor statusNuclear gradeIntraepithelial neoplasiaSame tumorHormonal therapyDifferent nuclear gradesHospital tumor registryMedian patient ageMajority of patientsLobular intraepithelial neoplasiaDin-2DIN 1Cohort of interestDIN patientsPR positivityPatient ageER statusPR statusTumor RegistrySingle pathologistInvasive tumorsSame patientPatients